Novo Nordisk Lifts 2026 Outlook as Wegovy Tablet Reaches Mexico

Novo Nordisk has raised its full-year 2026 guidance for both adjusted revenue and adjusted operating profit growth, the company said alongside its third-quarter results. At constant exchange rates, it now expects each measure to land between minus 2% and plus 2%, a band that still leaves room for either contraction or expansion. The previous range for both had been minus 6% to 0%.

The upgrade came as the Danish drugmaker reported adjusted revenue growth of 4% at constant currencies for the third quarter of 2026. Adjusted operating profit climbed 27% to DKK 31.72 billion.

Oral Wegovy Opens in Mexico

Separately, Novo has launched Wegovy tablets in Mexico, the first Latin American country to receive its oral obesity therapy. The Mexican medicines regulator COFEPRIS approved the pills in August. Availability is set to widen in stages over the coming weeks toward an estimated 10,000 points of sale, against a potential market Novo puts at 7.5 million people.

Whether that reach translates into prescriptions is the next test. Novo cites survey data showing more than 77% of adults would be more likely to start treatment if it came as a tablet, while fewer than 1% of people with overweight or obesity in Mexico currently receive any such care. Pricing is to be competitive by dose and sales channel and close to the injectable version, with a prescription and medical supervision still required.

Clinical Base and Rollout History

The Phase 3 OASIS 4 trial showed roughly 17% weight loss after 64 weeks, giving the launch a clinical footing. The approval covers long-term weight reduction in adults with obesity, or with overweight plus a weight-related comorbidity, as well as a reduction in major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. Since the Wegovy pill first launched, cumulative prescriptions have topped 8 million.

Liver Data Round Out the Week

Novo also presented new real-world data on semaglutide on 6 November from the PLATINUM-Truveta and RHODIUM-2 studies, covering adults with MASH and semaglutide at a 2.4 mg dose. Both examine liver health and cardiometabolic outcomes. A previously published post-hoc analysis of the Phase 3 ESSENCE trial, covering 106 adults with MASH and liver scarring and a body mass index below 27 kg/m², reported improvements in measures of liver damage, fibrosis and disease activity after 72 weeks versus placebo. Novo explicitly labelled that exploratory analysis as hypothesis-generating.

The Mexican rollout fits Novo's shift toward a higher-volume, lower-priced model. For investors, the question is whether added treatments can offset the pressure from softer prices — and whether the wider footprint turns into durable prescription growth.